The Phase 3 study for Sarclisa® (isatuximab) delays disease progression in newly diagnosed multiple myeloma patients who are unsuitable for stem cell transplantation.

PARP1 inhibitors are a class of drugs that target the PARP1 enzyme, crucial for DNA repair, and are particularly effective against certain cancers.

Wave Life Sciences has launched the first stage of treatment in its RestorAATion study, which assesses the pioneering RNA editing treatment, WVE-006, aimed at combatting Alpha-1 Antitrypsin Deficiency.

Active targeting of a drug is typically achieved by conjugating it to a target entity that improves bioavailability and reduces systemic toxicity.

CatalYm Reports Promising Results for Phase 2a Trial with Visugromab Treating Late-Stage NSCLC and Bladder Cancer During the 2023 ESMO Immuno-Oncology Meeting.

PDE3 inhibitors are drugs that target the PDE3 enzyme, crucial for regulating cellular signaling pathways.

Bolt Biotherapeutics Commences Phase 2 Clinical Trial Enrollment for BDC-1001 in HER2-Positive Breast Cancer Subjects Previously Administered Enhertu.

As indicated, effective use of protein drugs can be compromised by their instability in the body, rapid rates of clearance, premature uptake by tissues and immunogenicity or antigenicity.

Coherus Showcases Early-Stage Study Results for its Novel IL-27-Specific Antibody, Casdozokitug, at ESMO's 2023 Immuno-Oncology Meeting.

PCSK9 inhibitors can significantly reduce LDL-C levels, and the development of related drugs is of great importance for the treatment of cardiovascular diseases.

Qilu Pharma Reports Data on Phase 2 Trial of Iparomlimab in Treating Progressive Solid Cancers, Reveals 45.8% Objective Response Rate at ESMO Asia Conference.

Pharmacometric models describe the current understanding of the drug/therapy and simulations help predict next steps for testing the drug in animals and humans.